Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
Authors
Keywords
-
Journal
ANNALS OF HEMATOLOGY
Volume 98, Issue 12, Pages 2749-2760
Publisher
Springer Science and Business Media LLC
Online
2019-11-19
DOI
10.1007/s00277-019-03830-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program
- (2018) Peter Hillmen et al. HAEMATOLOGICA
- Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program
- (2018) Peter Hillmen et al. HAEMATOLOGICA
- PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies
- (2018) Jamie Garside et al. Journal of Comparative Effectiveness Research
- Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies
- (2018) Tadeusz Robak et al. AMERICAN JOURNAL OF HEMATOLOGY
- NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017
- (2017) William G. Wierda et al. Journal of the National Comprehensive Cancer Network
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
- (2017) J R Brown et al. LEUKEMIA
- Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
- (2017) Marc L. Berger et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Non-Hodgkin’s Lymphomas
- (2017) Andrew D. Zelenetz et al. Journal of the National Comprehensive Cancer Network
- Non-Hodgkin’s Lymphomas, Version 1.2013
- (2017) Andrew D. Zelenetz et al. Journal of the National Comprehensive Cancer Network
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.
- (2016) Miguel A. Hernán et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) B. Eichhorst et al. ANNALS OF ONCOLOGY
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
- (2014) Matthew S Davids et al. Future Oncology
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers
- (2013) T. Shanafelt Hematology-American Society of Hematology Education Program
- ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
- (2012) M. Ghielmini et al. ANNALS OF ONCOLOGY
- Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
- (2010) M. Sant et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started